Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 15.65 -0.3 (1.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.95 | 52 Week High | $117.12 | |||
| Open | $15.92 | 52 Week Low | $46.52 | |||
| Day High | $15.94 | P/E | N/A | |||
| Day Low | $15.49 | EPS | $-1.97 | |||
| Volume | 1,789,646 | |||||
